Zynerba pharmaceuticals stock.

13.04% of Zynerba Pharmaceuticals stock is owned by insiders. Learn more on ZYNE's insider holdings. Which Zynerba Pharmaceuticals insiders have been selling company stock? The following insiders have sold ZYNE shares in the last 24 months: Armando Anido ($58,074.60), Brian Rosenberger ($20,842.33), Daniel L Kisner …Web15 thg 9, 2023 ... ... Zynerba Pharmaceuticals Inc (ZYNE) sold 12401 shares of the company's stock ... Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical ...InvestorPlace - Stock Market News, Stock Advice & Trading Tips. In a stunning turn of the tables, beleaguered cannabinoid therapeutics developer Zynerba Pharmaceuticals (NASDAQ:ZYNE) skyrocketed ...The Zynerba Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Aug 14, 2023 · About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically produced, synthetic transdermal cannabidiol therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome ... Oct 10, 2023 · Zynerba Pharmaceuticals (ZYNE) Add to portfolio. are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for ...

Harmony Biosciences (HRMY) traded lower pre-market Monday after announcing an agreement to acquire Zynerba Pharmaceuticals (ZYNE) for up to $200M cash. Read more here.value right (CVR) for each share of Common stock of Zynerba Pharmaceuticals, Inc. accepted in the offer. The CVR represents the contractual right to receive contingent cash payments, without interest and subject to any applicable withholding taxes, upon the terms and subject to the conditions set forth in the Offer. Exercise …

Here's Why Zynerba Pharmaceuticals Lost 21.8% in July Here's Why Zynerba Pharmaceuticals Stock Soared 356% in the First Half of the Year 5 Best Biotech Stocks of 2019 So FarWebNov 16, 2023. PLYMOUTH MEETING, Pa. , Nov. 16, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that. HARMONY BIOSCIENCES RANKED AMONG TOP 25 ...Harmony Biosciences (HRMY) traded lower pre-market Monday after announcing an agreement to acquire Zynerba Pharmaceuticals (ZYNE) for up to $200M cash. Read more here.21 Jul 22 Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park CapitalSearch for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.

MarketWatch: Stock Market News - Financial News - MarketWatch

Zynerba Pharmaceuticals stock price from Google Finance If the cash price on offer is $1.10 and the market price is $1.35 then clearly those contingents are currently valued at $0.25 each. Given that the payout is capped at about ten times that this may or may not be a reasonable valuation - that will be a matter of opinion of course.

Track Zynerba Pharmaceuticals Inc (ZYNE) Stock Price, Quote, latest community messages, chart, news and other stock related information.Oct 11, 2023 · Annual Meeting to Reconvene on August 25, 2023 at 9:00 a.m. EDT. Devon, PA, August 8, 2023 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the new date for the adjourned 2023 Annual Meeting of Stockholders (“Annual Meeting ... Renaissance Technologies LLC. 1.12. CSS LLC. 0.88. The latest Zynerba Pharmaceuticals stock prices, stock quotes, news, and ZYNE history to help you …If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...14 thg 8, 2023 ... Why Is Zynerba Pharmaceuticals (ZYNE) Stock Up 270% Today? · Shares of cannabinoid therapeutics developer Zynerba Pharmaceuticals (ZYNE) popped ...Harmony’s tender offer to acquire all outstanding shares of Zynerba for a purchase price of $1.1059 per share in cash, or $60 million in the aggregate, plus one non-tradeable contingent value right (CVR) per share, representing the right to receive potential additional payments of up to $140 million or approximately $2.5444 in additional cash ...Aug 14, 2023 · According to data from Benzinga Pro, more than 11 million shares have already been traded in the session, far surpassing the stock's 100-day average of 194,930 shares. Zynerba is a pharmaceutical ...

, New York City time, on Tuesday, September 26, 2023, a total of 17,298,313 shares of Zynerba's common stock were validly tendered and not withdrawn in the tender offer, which represent ...Devon, PA, November 2, 2022 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,458,109, titled “Treatment of 22q11.2 Deletion Syndrome …WebJul 21, 2022 · Devon, PA, July 21, 2022 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced it has entered into an equity purchase agreement for up to $20 million with Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor. Under the terms of the ... Harmony’s tender offer to acquire all outstanding shares of Zynerba for a purchase price of $1.1059 per share in cash, or $60 million in the aggregate, plus one …Target values for the price of one Zynerba share for Jan 2025. The weighted average target price per Zynerba share in Jan 2025 is: 2.21. In Jan, the Positive dynamics for Momo shares will prevail with possible monthly volatility of 16.403% volatility is expected. Pessimistic target level: 2.00. Optimistic target level: 2.40.WebShares of Zynerba Pharmaceuticals (NASDAQ: ZYNE) of Devon were trading at 33 cents per share in late morning trading Wednesday. The company's shareholders will vote on the reverse stock split at ...Zynerba Pharmaceuticals (ZYNE) Quote Overview » More Research » Zynerba Pharmaceuticals (ZYNE) Price Target Stock Forecast Better trading starts here. N/A (ZYNE) Price Targets

Zynerba Pharmaceuticals (ZYNE) Quote Overview » More Research » Zynerba Pharmaceuticals (ZYNE) Price Target Stock Forecast Better trading starts here. N/A (ZYNE) Price Targets

Aug 14, 2023 · Zynerba Pharmaceuticals ( NASDAQ: ZYNE ), a drug developer focused on rare neuropsychiatric disorders, added ~276% in the morning hours Monday after Harmony Biosciences ( NASDAQ: HRMY) agreed to ... According to the issued ratings of 4 analysts in the last year, the consensus rating for Zynerba Pharmaceuticals stock is Hold based on the current 3 hold ratings and 1 buy …Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...Sep 27, 2023 · The depositary for the tender offer has advised that, as of 5:00 p.m., New York City time, on Tuesday, September 26, 2023, a total of 17,298,313 shares of Zynerba's common stock were validly ... Sep 29, 2023 · Devon, PA, September 29, 2023 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today released the following letter to stockholders concerning the pending tender offer by Harmony Biosciences Holdings, Inc. (“Harmony”). Fellow Zynerba Pharmaceuticals Stockholders, We ... DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan ...Zynerba Pharmaceuticals Stock Prediction 2025. The Zynerba Pharmaceuticals stock prediction for 2025 is currently $ 0.950071, assuming that Zynerba Pharmaceuticals shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a -26.92% increase in the ZYNE stock price.

Oct 11, 2023 · The depositary for the tender offer has advised that, as of the expiration of the tender offer, a total of 28,236,148 shares of Zynerba's common stock were validly tendered and not withdrawn in ...

The therapy is being developed for patients suffering from FXS, ASD in paediatric patients, and a group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE). The firm is listed on the NASDAQ under the stock ticker ZYNE. Monitor the Zynerba share price by adding ZYNE stock to your eToro watchlist today.

Oct 12, 2023 · Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for ... Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.So, make sure to keep an eye on this stock going forward, to see if this recent move higher can last. Zynerba Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.WebZynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and …In addition, Zynerba Pharmaceuticals, Inc. has a VGM Score of D ... A stock with a P/E ratio of 20, for example, is said to be trading at 20 times its annual earnings.Legal Name Zynerba Pharmaceuticals, Inc. Stock Symbol NASDAQ:ZYNE. Company Type For Profit. Phone Number +1 484 581 7505. Zynerba Pharmaceuticals is dedicated to the development of innovative transdermal cannabinoid treatments for patients with high unmet medical needs using modern drug delivery technology and appropriate regulatory …WebZynerba is an orphan-focused, neuropsychiatric, biopharmaceutical company taking a different and exciting transdermal approach to cannabinoids. Zynerba Pharmaceuticals has been acquired by Harmony Biosciences, a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases ... Oct 11, 2023 · The depositary for the tender offer has advised that, as of the expiration of the tender offer, a total of 28,236,148 shares of Zynerba's common stock were validly tendered and not withdrawn in ... Zynerba Pharmaceuticals, Inc. (ZYNE) Latest Stock News & Headlines - Yahoo Finance My Portfolio Markets Videos Zynerba Pharmaceuticals, Inc. (ZYNE) NasdaqCM - NasdaqCM Real Time Price....Aug 14, 2023 · To participate in the live call by phone, dial (800) 245-3047 (domestic) or +1 (203) 518-9765 (international), and reference passcode HRMY0814. About Harmony Biosciences. At Harmony Biosciences ... Clinical Trials Zynerba is conducting clinical studies of Zygel™ in a number of patients with neuropsychiatric conditions in the U.S., Australia, New Zealand and Europe, including the UK. Zygel is an investigational treatment. This means that it is not approved by government regulatory bodies, including the U.S. Food and Drug Administration (FDA). FXS …Web

Harmony’s tender offer to acquire all outstanding shares of Zynerba for a purchase price of $1.1059 per share in cash, or $60 million in the aggregate, plus one non-tradeable contingent value right (CVR) per share, representing the right to receive potential additional payments of up to $140 million or approximately $2.5444 in additional cash ...Benzinga Aug. 14, 2023, 10:21 AM Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) shares are skyrocketing Monday after Harmony Biosciences (NASDAQ:HRMY) …, New York City time, on Tuesday, September 26, 2023, a total of 17,298,313 shares of Zynerba's common stock were validly tendered and not withdrawn in the tender offer, which represent ...Instagram:https://instagram. best dividend trackerraytheon share pricetop online mortgage companiesflmng Zynerba Stock Forecast 12-01-2023. Forecast target price for 12-01-2023: $ 1.34. Positive dynamics for Zynerba shares will prevail with possible volatility of 8.228%. Pessimistic target level: 1.26. Optimistic target level: 1.38. online real estate investing platformhighest rated 529 plans Devon, PA, September 29, 2023 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today released the following letter to stockholders concerning the pending tender offer by Harmony Biosciences Holdings, Inc. (“Harmony”). Fellow Zynerba Pharmaceuticals Stockholders, We ... best companies to day trade Aug 14, 2023 · InvestorPlace - Stock Market News, Stock Advice & Trading Tips. In a stunning turn of the tables, beleaguered cannabinoid therapeutics developer Zynerba Pharmaceuticals (NASDAQ:ZYNE) skyrocketed ... Annual Meeting to Reconvene on August 25, 2023 at 9:00 a.m. EDT. Devon, PA, August 8, 2023 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the new date for the adjourned 2023 Annual Meeting of Stockholders (“Annual Meeting ...Zynerba Pharmaceuticals information: analysis, Share Price, stock price history, price chart, dividends, financials, key metrics, number of shares, ...